Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 1, 2003, Pages 101-108

  Lehtiö, Kaisa ^a   Oikonen, Vesa ^b   Nyman, Samuel ^b   Grönroos, Tove ^c   Roivainen, Anne ^a   Eskola, Olli ^d   Minn, Heikki ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

^d TURKU PET CENTRE   (Finland)

Author keywords

18F fluoroerythronitroimidazole; Hypoxia; Modelling; PET; Radiotherapy

Indexed keywords

FLUOROERYTHRONITROIMIDAZOLE F 18; NITROIMIDAZOLE DERIVATIVE; UNCLASSIFIED DRUG; WATER O 15;

ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISTRIBUTION VOLUME; DRUG UPTAKE; HEAD AND NECK CANCER; HUMAN; HYPOXEMIA; MUSCLE BLOOD FLOW; PLASMA; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; RADIOSENSITIVITY; SQUAMOUS CELL CARCINOMA; TISSUE OXYGENATION;

BLOOD FLOW VELOCITY; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; FLUORINE RADIOISOTOPES; HEAD AND NECK NEOPLASMS; HUMANS; MUSCLE, SKELETAL; NITROIMIDAZOLES; OXYGEN RADIOISOTOPES; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0038207686     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-002-1016-x     Document Type: Article

References (26)

1. Hall EJ. Radiosensitizers and bioreductive drugs. In: Hall EJ, ed. Radiobiology for the radiologist. Philadelphia: Lippincott; 1994:165-181.
2. Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 2000; 6:157-162.
3. Nordsmark M, Bentzen SM, Overgaard J. Measurement of human tumour oxygenation status by a polarographic needle electrode. An analysis of inter- and intratumour heterogeneity. Acta Oncol 1994; 33:383-389.
4. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996; 41:31-39.
5. Chapman JD, Schneider RF, Urbain JL, Hanks GE. Singlephoton emission computed tomography and positron-emission tomography assays for tissue oxygenation. Semin Radiat Oncol 2001; 11:47-57.
6. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995; 22:265-280.
7. Casciari JJ, Graham MM, Rasey JS. A modeling approach for quantifying tumor hypoxia with [F-18]fluoromisonidazole PET time-activity data. Med Phys 1995; 22:1127-1139.
8. Yang DJ, Wallace S, Cherif A, Li C, Gretzer MB, Kim EE, Podoloff DA. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology 1995; 194:795-800.
9. 18F]Fluoroerythronitroimidazole PET. J Nucl Med 2001; 42:1643-1652.
10. Grönroos T, Eskola O, Lehtiö K, Minn H, Marjamäki P, Bergman J, Haaparanta M, Forsback S, Solin O. Pharmacokinetics of [18F]FETNIM: a potential marker for PET. J Nucl Med 2001; 42:1397-1404.
11. Varghese AJ, Whitmore GF. Binding to cellular macromolecules as a possible mechanism for the cytotoxicity of misonidazole. Cancer Res 1980; 40:2165-2169.
12. Chapman JD, Baer K, Lee J. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Res 1983; 43:1523-1528.
13. Patlak CS, Blasberg RG. Graphical evaluation of blood-tobrain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985; 5:584-590.
14. 11C -methyl]-(-)cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990; 10:740-747.
15. Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol 2000; 27:661-670.
16. Miller GG, Ngan-Lee J, Chapman JD. Intracellular localization of radioactively labeled misonidazole in EMT-6-tumor cells in vitro. Int J Radiat Oncol Biol Phys 1982; 8:741-744.
17. Chapman JD, Zanzonico P, Ling CC. On measuring hypoxia in individual tumors with radiolabeled agents. J Nucl Med 2001; 42:1653-1655.
18. Chapman JD, McPhee MS, Walz N, Chetner MP, Stobbe CC, Soderlind K, Arnfield M, Meeker BE, Trimble L, Allen PS. Nuclear magnetic resonance spectroscopy and sensitizeradduct measurements of photodynamic therapy-induced ischemia in solid tumors. J Natl Cancer Inst 1991; 83:1650-1659.
19. Iyer RV, Engelhardt EL, Stobbe CC, Schneider RF, Chapman JD. Preclinical assessment of hypoxic marker specificity and sensitivity. Int J Radiat Oncol Biol Phys 1998; 42:741-745.
20. Nordsmark M, Loncaster J, Chou SC, Havsteen H, Lindegaard JC, Davidson SE, Varia M, West C, Hunter R, Overgaard J, Raleigh JA. Invasive oxygen measurements and pimonidazole labeling in human cervix carcinoma. Int J Radiat Oncol Biol Phys 2001; 49:581-586.
21. Raleigh JA, Chou SC, Arteel GE, Horsman MR. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res 1999; 151:580-589.
22. Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996; 6:10-21.
23. Overgaard J. Overcoming hypoxic cell radioresistance. In: Steel GG, ed. Basic clinical radiobiology for radiation oncologists. London: Edward Arnold; 1997:141-151.
24. 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 1999; 40:177-183.
25. Hartmann KA, van der Kleij AJ, Carl UM, Hulshof MC, Willers R, Sminia P. Effects of hyperbaric oxygen and normobaric carbogen on the radiation response of the rat rhabdomyosarcoma R1H(1). Int J Radiat Oncol Biol Phys 2001; 51:1037-1044.
26. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58:1408-1416.